Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. TaxStatus is the only firm to provide the comprehensive information advisors need to ...